Reviva Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments · last filed 2023-05-15
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2023-03-31 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2021-12-31 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2021-09-30 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2022 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2021 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-30 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |